Analysts Expect China Biologic Products, Inc. (CBPO) Will Announce Earnings of $1.30 Per Share

Brokerages forecast that China Biologic Products, Inc. (NASDAQ:CBPO) will announce earnings of $1.30 per share for the current quarter, according to Zacks. Zero analysts have issued estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $1.22 in the same quarter last year, which would suggest a positive year over year growth rate of 6.6%. The company is expected to announce its next quarterly earnings report on Wednesday, November 1st.

On average, analysts expect that China Biologic Products will report full year earnings of $5.02 per share for the current fiscal year. For the next year, analysts expect that the firm will report earnings of $5.86 per share, with EPS estimates ranging from $5.78 to $5.93. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for China Biologic Products.

China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.05. The company had revenue of $89.28 million for the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 earnings per share.

A number of brokerages have issued reports on CBPO. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Monday, August 7th. BidaskClub cut shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of China Biologic Products in a report on Tuesday, May 30th. They set a “neutral” rating on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $132.00.

Shares of China Biologic Products (NASDAQ:CBPO) traded up 1.74% during midday trading on Friday, reaching $94.99. The company had a trading volume of 320,624 shares. The company has a 50 day moving average price of $94.61 and a 200-day moving average price of $104.58. The firm has a market capitalization of $2.59 billion, a P/E ratio of 24.74 and a beta of 1.75. China Biologic Products has a one year low of $88.25 and a one year high of $126.47.

TRADEMARK VIOLATION WARNING: “Analysts Expect China Biologic Products, Inc. (CBPO) Will Announce Earnings of $1.30 Per Share” was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/09/10/analysts-expect-china-biologic-products-inc-cbpo-will-announce-earnings-of-1-30-per-share.html.

Several institutional investors have recently added to or reduced their stakes in CBPO. BlackRock Inc. increased its holdings in shares of China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after purchasing an additional 1,318,183 shares during the period. Hillhouse Capital Management Ltd. increased its holdings in shares of China Biologic Products by 186.8% in the second quarter. Hillhouse Capital Management Ltd. now owns 753,624 shares of the biopharmaceutical company’s stock worth $85,235,000 after purchasing an additional 490,874 shares during the period. Schroder Investment Management Group increased its holdings in shares of China Biologic Products by 771.5% in the second quarter. Schroder Investment Management Group now owns 544,676 shares of the biopharmaceutical company’s stock worth $60,845,000 after purchasing an additional 482,175 shares during the period. FMR LLC increased its holdings in shares of China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock worth $188,300,000 after purchasing an additional 406,105 shares during the period. Finally, Macquarie Group Ltd. increased its holdings in shares of China Biologic Products by 115.3% in the second quarter. Macquarie Group Ltd. now owns 587,587 shares of the biopharmaceutical company’s stock worth $66,456,000 after purchasing an additional 314,700 shares during the period. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

China Biologic Products Company Profile

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply